These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24480288)

  • 21. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early, late, or no shunt embolization in patients with cirrhosis- and portosystemic shunt-related hepatic encephalopathy.
    Philips CA; Rajesh S; George T; Ahamed R; Mohanan M; Augustine P
    Indian J Gastroenterol; 2020 Aug; 39(4):377-387. PubMed ID: 32929684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2153-60. PubMed ID: 25352391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
    Morgan MY
    Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of first overt episode of hepatic encephalopathy after TIPS: no easy task.
    Mullen KD; Ghanta RK; Putka BS
    Hepatology; 2006 May; 43(5):1155-6. PubMed ID: 16628645
    [No Abstract]   [Full Text] [Related]  

  • 27. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
    Tapper EB; Finkelstein D; Mittleman MA; Piatkowski G; Chang M; Lai M
    Clin Gastroenterol Hepatol; 2016 May; 14(5):753-9. PubMed ID: 26407750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Agrawal A; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2011 Jun; 26(6):996-1003. PubMed ID: 21129028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hepatic encephalopathy and liver transplantation].
    Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L
    Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
    Morgan MY; Hawley KE
    Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
    Morgan MY; Alonso M; Stanger LC
    J Hepatol; 1989 Mar; 8(2):208-17. PubMed ID: 2654285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of hepatic encephalopathy in cirrhosis.
    Romero-Gómez M
    Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and emerging strategies for treating hepatic encephalopathy.
    Foster KJ; Lin S; Turck CJ
    Crit Care Nurs Clin North Am; 2010 Sep; 22(3):341-50. PubMed ID: 20691385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
    Heredia D; Terés J; Orteu N; Rodés J
    J Hepatol; 1988 Aug; 7(1):106-10. PubMed ID: 3053887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.